EFFECTIVENESS OF 12 OR 24 WEEK LDV/SOF AND 12 WEEK LDV/SOF+RBV IN TREATMENT-EXPERIENCED PATIENTS WITH CIRRHOTIC, GENOTYPE 1 HEPATITIS C: REAL-WORLD EXPERIENCE FROM THE TRIO NETWORK

  • Curry M
  • Bacon B
  • Dieterich D
  • et al.
N/ACitations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

BACKGROUND: The current recommendations for treatment of cirrhosis in HCV genotype 1 patients are dependent on prior treatment. 12 week ledipasvir/sofosbuvir (LDV/SOF) is recommended in treatment-naive patients whereas 24 week LDV/ SOF is recommended for prior treatment failures. In addition, 12 week LDV/SOF + RBV has been suggested as an alternative to 24 week LDV/SOF for treatment failures (Bourliere M, et al. Abs #82, AASLD 2014). No data is really available comparing these regimens in real-world patients that previously failed treatment. AIM: To evaluate real-world SVR12 in treatment failure patients with HCV genotype 1 and cirrhosis treated with 12 or 24 weeks of LDV/SOF or 12 weeks of LDV/SOF + RBV. METHODS: Data were obtained through Trio Health's Innervation Platform, a cloud-based disease management platform, and directly from specialty pharmacies for 250 treatment-experienced, genotype 1 patients with cirrhosis that initiated LDV/SOF +/- RBV between Oct 2014 and Mar 2015. 20% (50/250) of the patients were treated in community practices with the remainder from academic centers. RESULTS: Patient demographics for 3 groups are shown in the table. Intended treatments were: 21% (52/250 patients) 12 week LDV/SOF, 72% (180/250) 24 week LDV/SOF and 7% (18/250) 12 week LDV/SOF + RBV. SUMMARY: An examination of a real-world heterogeneous Hepatitis C population revealed a preference for 24 week LDV/SOF in this sample of treatment-experienced patients with cirrhotic genotype 1 HCV. The use of 12 week LDV/SOF + RBV is minimal, suggesting that RBV was viewed as an unnecessary addition to the shorter duration course, though subsequent analyses may find a shift in preferences. SVR data on this population will be available at the meeting. (Table Presented).

Cite

CITATION STYLE

APA

Curry, M., Bacon, B., Dieterich, D., Flamm, S., Guest, L., Kowdley, K., … Younossi, Z. (2016). EFFECTIVENESS OF 12 OR 24 WEEK LDV/SOF AND 12 WEEK LDV/SOF+RBV IN TREATMENT-EXPERIENCED PATIENTS WITH CIRRHOTIC, GENOTYPE 1 HEPATITIS C: REAL-WORLD EXPERIENCE FROM THE TRIO NETWORK. Value in Health, 19(3), A312–A313. https://doi.org/10.1016/j.jval.2016.03.991

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free